Weidung, Bodil;
Hemmingsson, Eva-Stina;
Olsson, Jan;
Sundström, Torbjörn;
Blennow, Kaj;
Zetterberg, Henrik;
Ingelsson, Martin;
... Lövheim, Hugo; + view all
(2022)
VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease.
Alzheimer's and Dementia: Translational Research and Clinical Interventions
, 8
(1)
, Article e12264. 10.1002/trc2.12264.
Preview |
PDF
Zetterberg_VALZ-Pilot High-dose valacyclovir treatment in patients with early-stage.pdf - Published Version Download (963kB) | Preview |
Abstract
Introduction: Herpes simplex virus (HSV) may be involved in Alzheimer's disease (AD) pathophysiology. The antiviral valacyclovir inhibits HSV replication. Methods: This phase-II pilot trial involved valacyclovir administration (thrice daily, 500 mg week 1, 1000 mg weeks 2-4) to persons aged ≥ 65 years with early-stage AD, anti-HSV immunoglobulin G, and apolipoprotein E ε4. Intervention safety, tolerability, feasibility, and effects on Mini-Mental State Examination (MMSE) scores and cerebrospinal fluid (CSF) biomarkers were evaluated. Results: Thirty-two of 33 subjects completed the trial on full dosage. Eighteen percent experienced likely intervention-related mild, temporary adverse events. CSF acyclovir concentrations were mean 5.29 ± 2.31 μmol/L. CSF total tau and neurofilament light concentrations were unchanged; MMSE score and CSF soluble triggering receptor expressed on myeloid cells 2 concentrations increased (P = .02 and .03). Discussion: Four weeks of high-dose valacyclovir treatment was safe, tolerable, and feasible in early-stage AD. Our findings may guide future trial design.
| Type: | Article |
|---|---|
| Title: | VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1002/trc2.12264 |
| Publisher version: | https://doi.org/10.1002/trc2.12264 |
| Language: | English |
| Additional information: | © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| Keywords: | Alzheimer's disease, apolipoprotein E ε4, feasibility study, herpes simplex, pilot project, valacyclovir |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10147447 |
Archive Staff Only
 |
View Item |
